Epalrestat effects on diabetic neuropathy
Epalrestat effects on diabetic neuropathy
Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease.
Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.
Recently, three aldose reductase inhibitors—Epalrestat, fidarestat, and ranirestat— have been evaluated in placebo-controlled clinical trials. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. It is the only drug available in the aldose reductase inhibitor class and was approved in Japan in 1992.
Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.
Recently, three aldose reductase inhibitors—Epalrestat, fidarestat, and ranirestat— have been evaluated in placebo-controlled clinical trials. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. It is the only drug available in the aldose reductase inhibitor class and was approved in Japan in 1992.
koko11- Posts : 17
Join date : 2010-04-21
Similar topics
» Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy
» Caveolin-1 upregulation in diabetic fibroblasts and wounded tissues: implication for understanding the underlying mechanisms of non-healing diabetic ulcers
» Targeting erythropoietin protects against proteinuria in type 2 diabetic patients and in zebrafish
» ELMO1 protects renal structure and ultrafiltration in kidney development and under diabetic conditions
» Altered RNA metabolism due to a homozygous RBM7 mutation in a patient with spinal motor neuropathy
» Caveolin-1 upregulation in diabetic fibroblasts and wounded tissues: implication for understanding the underlying mechanisms of non-healing diabetic ulcers
» Targeting erythropoietin protects against proteinuria in type 2 diabetic patients and in zebrafish
» ELMO1 protects renal structure and ultrafiltration in kidney development and under diabetic conditions
» Altered RNA metabolism due to a homozygous RBM7 mutation in a patient with spinal motor neuropathy
Permissions in this forum:
You cannot reply to topics in this forum
|
|